Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Current Opinion in Pharmacology
|
November 21, 2017
Ensuring quality pharmacokinetic analyses in antimicrobial drug development programs
Elizabeth A Lakota, Justin C Bader, Christopher M Rubino
Antimicrobial Agents and Chemotherapy
|
March 21, 2018
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
Elizabeth A Lakota, Voon Ong, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy
|
March 29, 2019
Erratum for Lakota et al., "Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data"
Elizabeth A Lakota, Voon Ong, Shawn Flanagan, et al.
Journal of Clinical Pharmacology
|
April 12, 2019
Drug-Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned
Islam R Younis, Elizabeth A Lakota, Donna A Volpe, et al.
Antimicrobial Agents and Chemotherapy
|
June 12, 2019
Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution
Elizabeth A Lakota, Nobuo Sato, Tomokazu Koresawa, et al.
Open Forum Infectious Diseases
|
December 25, 2018
Time for Precision: A World Without Susceptibility Breakpoints
Justin C Bader, Elizabeth A Lakota, David R Andes, et al.
Antimicrobial Agents and Chemotherapy
|
August 1, 2018
Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes
Elizabeth A Lakota, Cornelia B Landersdorfer, Li Zhang, et al.
Antimicrobial Agents and Chemotherapy
|
May 16, 2018
Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm
Elizabeth A Lakota, Cornelia B Landersdorfer, Roger L Nation, et al.
Antimicrobial Agents and Chemotherapy
|
March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
Justin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy
|
April 15, 2020
Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment <i>In Vitro</i> Infection Model
Brian D VanScoy, Elizabeth A Lakota, Haley Conde, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Current Opinion in Pharmacology
|
November 21, 2017
Ensuring quality pharmacokinetic analyses in antimicrobial drug development programs
Elizabeth A Lakota, Justin C Bader, Christopher M Rubino
Antimicrobial Agents and Chemotherapy
|
March 21, 2018
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
Elizabeth A Lakota, Voon Ong, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy
|
March 29, 2019
Erratum for Lakota et al., "Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data"
Elizabeth A Lakota, Voon Ong, Shawn Flanagan, et al.
Journal of Clinical Pharmacology
|
April 12, 2019
Drug-Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned
Islam R Younis, Elizabeth A Lakota, Donna A Volpe, et al.
Antimicrobial Agents and Chemotherapy
|
June 12, 2019
Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution
Elizabeth A Lakota, Nobuo Sato, Tomokazu Koresawa, et al.
Open Forum Infectious Diseases
|
December 25, 2018
Time for Precision: A World Without Susceptibility Breakpoints
Justin C Bader, Elizabeth A Lakota, David R Andes, et al.
Antimicrobial Agents and Chemotherapy
|
August 1, 2018
Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes
Elizabeth A Lakota, Cornelia B Landersdorfer, Li Zhang, et al.
Antimicrobial Agents and Chemotherapy
|
May 16, 2018
Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm
Elizabeth A Lakota, Cornelia B Landersdorfer, Roger L Nation, et al.
Antimicrobial Agents and Chemotherapy
|
March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
Justin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy
|
April 15, 2020
Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment <i>In Vitro</i> Infection Model
Brian D VanScoy, Elizabeth A Lakota, Haley Conde, et al.
Page
of 2